J. Zeng

Most-cited papers

1. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.

   K. Reich, H. Teixeira, M. D. de Bruin-Weller, T. Bieber +10 more

   2021The Lancet260 citations

   Semantic Scholar

   Save

2. Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results.

   J. Silverberg, M. D. de Bruin-Weller, T. Bieber, W. Soong +10 more

   2021Journal of Allergy and Clinical Immunology111 citations Open access

   Semantic Scholar

   Save

3. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

   M. Mohamed, J. Zeng, P. Marroum, I. Song +1 more

   2018Clinical pharmacology in drug development57 citations Open access

   Semantic Scholar

   Save

4. Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

   G. Goss, E. Vokes, M. Gordon, L. Gandhi +15 more

   2018Cancer56 citations Open access

   Semantic Scholar

   Save

5. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

   J. Berlin, R. Ramanathan, J. Strickler, Deepa S. Subramaniam +11 more

   2018British Journal of Cancer27 citations Open access

   Semantic Scholar

   Save

6. Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

   M. Gooderham, A. Pinter, L. Ferris, R. Warren +7 more

   2022Journal of the European Academy of Dermatology and Venereology19 citations Open access

   Semantic Scholar

   Save

7. Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity

   M. Mohamed, J. Zeng, P. Jiang, B. Hosmane +1 more

   2017Clinical pharmacology and therapy19 citations Open access

   Semantic Scholar

   Save

8. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus

   M. Minocha, J. Zeng, J. Medema, A. Othman

   2018Clinical Pharmacokinetics12 citations

   Semantic Scholar

   Save

9. Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

   K. Papp, Saskia de Vente, J. Zeng, M. Flack +2 more

   2021Dermatologic Therapy11 citations Open access

   Semantic Scholar

   Save

10. ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR).

    G. Goss, E. Vokes, M. Gordon, L. Gandhi +14 more

    20155 citations

    Semantic Scholar

    Save

11. Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

    K. Reich, H. Teixeira, M. D. de Bruin-Weller, Thomas Bieber +10 more

    2021Social Science Research Network2 citations

    Semantic Scholar

    Save

12. 14027 Long-term efficacy and safety of continuous q12w risankizumab: Results from the open-label extension LIMMitless trial

    K. Papp, M. Lebwohl, J. Zeng, S. Rubant +2 more

    20202 citations

    Semantic Scholar

    Save

13. 26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial

    K. Papp, M. Lebwohl, L. Puig, J. Zeng +5 more

    20211 citations

    Semantic Scholar

    Save

14. 27454 Efficacy and safety of long-term risankizumab re-treatment following drug withdrawal: IMMhance trial

    R. Langley, S. Tyring, A. Igarashi, S. Philipp +3 more

    20210 citations

    Semantic Scholar

    Save